UNIQURE NV Insider Buy: Exec Buys 10,295 Shares Amid Positive AMT‑260 Data Hype

Insider Buying Spree Amidst a Surge in Media Buzz

Balachandran Madhavan, a senior executive at UNIQURE NV, executed a sizable Rule 10b‑5‑1 sales‑plan trade on 17 June 2026, purchasing 10 295 shares at an average price of $31.71. The transaction brought his post‑trade ownership to 49 644 shares, representing roughly 2 % of the outstanding float. While the purchase price is only modestly above the day’s close of $39.35, the trade is noteworthy because it follows a series of large sells earlier that month – including a 5 295‑share sell at $47.08 and a 4 700‑share sell at $43.66 – that collectively reduced his stake to 44 944 shares. The net effect is an incremental position that suggests confidence in the company’s near‑term catalysts.

Implications for Investors

The timing of Madhavan’s buy is significant. It coincides with the announcement of the Phase I/IIa data for AMT‑260, the first‑in‑class gene‑therapy candidate for refractory mesial temporal lobe epilepsy. Positive interim results and an ongoing second‑dose cohort create an earnings window that could drive share price appreciation in the first half of 2027. Investors may interpret the insider purchase as an endorsement of this trajectory, especially given the company’s historically volatile stock and a negative P/E of –13.71, which indicates that earnings are currently low relative to price. A 66.94% weekly gain and 92.84% monthly rise already point to strong momentum, but the insider action adds a layer of conviction that could catalyze further buying.

Madhavan’s Historical Trading Pattern

A review of Madhavan’s past filings shows a pattern of disciplined, rule‑based trading. He has frequently used the same March 10, 2026 10b‑5‑1 plan to buy and sell in equal volumes, often aligning purchases with the company’s share‑price ranges. For example, on 15 June 2026 he bought 10 000 shares at $8.49 and sold 10 000 shares at $27.85, a strategy that smooths out price volatility. His trades are generally executed at the lower end of the day’s price range, indicating a “buy low, sell high” mindset consistent with long‑term ownership. This pattern suggests that the current purchase is not a speculative play but part of a systematic approach to managing exposure.

Broader Insider Activity

The same day, other insiders, including Kaye Jack, executed both buys and sells, reflecting a broader rebalancing effort within the board. Kaye’s net position decreased from 31,291 to 25,996 shares after a $31.71 buy and a $42.57 sell, mirroring the company’s recent volatility. Such activity underscores the need for investors to monitor insider trades as a gauge of internal confidence, especially when the company is on the cusp of delivering clinically meaningful data.

Conclusion

Madhavan’s incremental purchase, set against a backdrop of positive clinical data, strong market buzz (buzz 438.85 % and sentiment –98), and a disciplined trading history, offers a compelling signal for long‑term investors. While the stock’s valuation remains below its 52‑week low, the insider confidence, combined with the potential upside from upcoming trial results, could position UNIQURE NV for a notable rally in the coming year. Investors should weigh this insider conviction against the company’s current earnings profile and regulatory pathway, but the buy signals an optimistic outlook for the gene‑therapy pioneer.